FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:1963-1965 November 13, 2003 Number 20 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Pfeffer, M. A. PubMed Citation

Beta-blockers, angiotensin-converting–enzyme (ACE) inhibitors, and aldosterone antagonists have been shown to reduce the overall risk of death as well as the risk of major nonfatal cardiovascular events when they are administered to patients with acute myocardial infarction who also have left ventricular systolic dysfunction, clinical evidence of heart failure, or both.^1,2 However, there remains a sizable subgroup of patients in whom clinical heart failure worsens despite optimal medical therapy after acute myocardial infarction. Relevant to this discussion is the observation that ACE inhibitors block only 13 percent of the total production of angiotensin II in the human heart³ because of . . . [Full Text of this Article]

Source Information

From the Medical Care Line, Houston Veterans Affairs Medical Center, and the Winters Center for Heart Failure Research, Baylor College of Medicine — both in Houston.

This article has been cited by other articles:

• Hall, A. S, Strauss, M. H (2007). More about the "ARB MI paradox". Heart 93: 1011-1014 [Abstract] [Full Text]  
• Azizi, M., Menard, J., Bissery, A., Guyene, T.-T., Bura-Riviere, A. (2007). Hormonal and Hemodynamic Effects of Aliskiren and Valsartan and Their Combination in Sodium-Replete Normotensive Individuals. CJASN 2: 947-955 [Abstract] [Full Text]  
• Yan, A. T., Yan, R. T., Liu, P. P. (2005). Narrative Review: Pharmacotherapy for Chronic Heart Failure: Evidence from Recent Clinical Trials. ANN INTERN MED 142: 132-145 [Abstract] [Full Text]  
• (2004). ARB, ACE Inhibitor, or Both After MI in High-Risk Patients?. Journal Watch Cardiology 2004: 5-5 [Full Text]  
• Azizi, M., Menard, J., Bissery, A., Guyenne, T.-T., Bura-Riviere, A., Vaidyanathan, S., Camisasca, R. P. (2004). Pharmacologic Demonstration of the Synergistic Effects of a Combination of the Renin Inhibitor Aliskiren and the AT1 Receptor Antagonist Valsartan on the Angiotensin II-Renin Feedback Interruption. J. Am. Soc. Nephrol. 15: 3126-3133 [Abstract] [Full Text]  
• Writing Committee Members, , Antman, E. M., Anbe, D. T., Armstrong, P. W., Bates, E. R., Green, L. A., Hand, M., Hochman, J. S., Krumholz, H. M., Kushner, F. G., Lamas, G. A., Mullany, C. J., Ornato, J. P., Pearle, D. L., Sloan, M. A., Smith, S. C. Jr, Task Force Members, , Antman, E. M., Smith, S. C. Jr, Alpert, J. S., Anderson, J. L., Faxon, D. P., Fuster, V., Gibbons, R. J., Gregoratos, G., Halperin, J. L., Hiratzka, L. F., Hunt, S. A., Jacobs, A. K., Ornato, J. P. (2004). ACC/AHA guidelines for the management of patients with ST-Elevation myocardial infarction--executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (writing committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction) . J Am Coll Cardiol 44: 671-719 [Full Text]  
• Antman, E. M., Anbe, D. T., Armstrong, P. W., Bates, E. R., Green, L. A., Hand, M., Hochman, J. S., Krumholz, H. M., Kushner, F. G., Lamas, G. A., Mullany, C. J., Ornato, J. P., Pearle, D. L., Sloan, M. A., Smith, S. C. Jr, Antman, E. M., Smith, S. C. Jr, Alpert, J. S., Anderson, J. L., Faxon, D. P., Fuster, V., Gibbons, R. J., Gregoratos, G., Halperin, J. L., Hiratzka, L. F., Hunt, S. A., Jacobs, A. K., Ornato, J. P. (2004). ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 110: 588-636 [Full Text]  
• Bauman, J. L., Talbert, R. L. (2004). Pharmacodynamics of{beta}-Blockers in Heart Failure: Lessons from the Carvedilol Or Metoprolol European Trial. J CARDIOVASC PHARMACOL THER 9: 117-128 [Abstract]  
• Cerbai, E., Mugelli, A. (2004). Angiotensin AT2 receptor: the younger sibling attracts attention. Cardiovasc Res 62: 7-8 [Full Text]  
• (2004). ARB, ACE Inhibitor, or Both After MI in High-Risk Patients?. Journal Watch Cardiology 2004: 1-1 [Full Text]  
• (2003). ARBs vs. ACE Inhibitors After Myocardial Infarction with LV Dysfunction. JWatch General 2003: 1-1 [Full Text]